MannKind Corporation (NASDAQ:MNKD) Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit September 22, 2021 2:55 PM ET Company Participants Michael Castagna - CEO Conference Call Participants Michael Castagna Good afternoon, and thank you for joining us on our Oppenheimer Healthcare Life Sciences & Med Tech Summit today. My name is Mike Castagna, I'm the CEO of MannKind and I'm here to try give you an update, really quickly for new investors on the company and for existing investors any key updates w ...

MannKind Corporation Conference Call Summary Company Overview - **Company**: MannKind Corporation (NASDAQ: MNKD) - **Industry**: Specialty Pharmaceuticals - **Key Product**: Tyvaso DPI, an inhalable drug delivery technology partnered with United Therapeutics Core Points and Arguments 1. **Increased Investor Interest**: There is heightened investor interest in MannKind, particularly with the upcoming PDUFA date for Tyvaso DPI in October 2021, marking a significant milestone for the company [3][4][5] 2. **Tyvaso DPI Overview**: Tyvaso DPI is a next-generation dry powder inhaler for pulmonary arterial hypertension, transitioning from a nebulized formulation that generates approximately $500 million annually [5][6] 3. **Technological Advancements**: The transition from nebulizer to dry powder inhaler allows for higher dosing capabilities, with studies showing the potential to administer doses three to four times higher than the current FDA-approved nebulizer dose without additional safety concerns [7][8] 4. **Patient Convenience**: The new inhaler design significantly reduces the complexity of treatment, allowing patients to carry it easily and administer it in two seconds, contrasting with the cumbersome nebulizer setup [11][12] 5. **Partnership with United Therapeutics**: The partnership includes a $105 million upfront payment, a $100 million priority review voucher, and ongoing investments exceeding $200 million, indicating a strong commitment from United Therapeutics [14][15] 6. **Clinical Data Confidence**: MannKind has confidence in the clinical data supporting Tyvaso DPI, with a well-structured clinical package and successful pre-approval inspections by the FDA [18][21][22] 7. **Market Potential**: United Therapeutics aims to double the patient population using Tyvaso from 3,000 to 6,000 by the end of 2022, with Tyvaso DPI expected to play a crucial role in this growth [31][32] 8. **Competitive Landscape**: There is competition from another company developing a dry powder version of treprostinil, but MannKind emphasizes the unique advantages of their technology and partnership with United Therapeutics [37][39][40] 9. **Intellectual Property**: MannKind's IP for Tyvaso DPI is expected to last into the 2030s, providing a competitive edge against potential generic versions [42][45] Additional Important Insights 1. **Afrezza Developments**: MannKind is also focusing on expanding the use of Afrezza, their inhalable insulin product, with plans to target pediatric populations and improve market penetration through better reimbursement strategies [46][48][49] 2. **Pipeline Expansion**: The company is investing in a pipeline that includes treatments for non-tuberculous mycobacterial infections, COVID-19, and idiopathic pulmonary fibrosis, indicating a broader strategic vision beyond Tyvaso DPI [53][54][55] 3. **Financial Position**: MannKind is well-capitalized with over $200 million in cash, allowing for continued investment in product development and marketing efforts [52] This summary encapsulates the key points discussed during the conference call, highlighting MannKind's strategic direction, product innovations, and market potential.

MannKind Corporation (NASDAQ:MNKD) Q2 2021 Earnings Conference Call August 11, 2021 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Stuart Tross - Head, Human Resources Conference Call Participants Brandon Folkes - Cantor Fitzgerald Daniel Busby - RBC Capital Markets Steve Lichtman - Oppenheimer Thomas Smith - SVB Leerink Bert Hazlett - BTIG Operator Good afternoon and welcome to the MannKind Corporation Second Quarter 2021 Earnings Call. As ...

MannKind Corporation (NASDAQ:MNKD) Lytham Partners Summer 2021 Investor Conference June 14, 2021 11:45 AM ET Company Participants Michael Castagna - CEO Conference Call Participants Robert Blum - Lytham Partners Robert Blum All right. Hello, everyone and thank you all for joining us during the Lytham Partners Summer 2021 Investor Conference. My name is Robert Blum, Managing Partner of Lytham Partners. Our next presentation comes from MannKind, ticker symbol of MNKD on the NASDAQ. Presenting from the Company ...

MannKind Corporation (NASDAQ:MNKD) 2021 RBC Capital Markets Global Healthcare Conference Call May 18, 2021 4:15 PM ET Company Participants Michael Castagna - Chief Executive Officer Conference Call Participants Daniel Busby - Pharmaceuticals Equity Research Analyst, RBC capital markets Daniel Busby I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets. Our next company presenting today is MannKind Corporation, which we recently initiated coverage on. And I'm pleased to be joined by Michael Casta ...